Uninterrupted anticoagulation with non‐vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials-Reference-Cited by-同舟云学术

Uninterrupted anticoagulation with non‐vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials

Published:2018-12-07 Issue:1 Volume:42 Page:198-205
ISSN:0160-9289
Container-title:Clinical Cardiology
language:en
Short-container-title:Clin Cardiol

Author:

Cardoso Rhanderson¹^ORCID,Willems Stephan²,Gerstenfeld Edward P.³,Verma Atul⁴,Schilling Richard⁵,Hohnloser Stefan H.⁶,Okumura Ken⁷,Nordaby Matias⁸,Brouwer Marc A.⁹,Calkins Hugh¹

Affiliation:

1. Division of CardiologyJohns Hopkins Medical Institutions Baltimore Maryland

2. Department of Cardiology‐ElectrophysiologyUniversity Heart Center Hamburg Hamburg Germany

3. Division of CardiologyUniversity of California San Francisco San Francisco California

4. Division of CardiologyUniversity of Toronto Toronto Canada

5. Division of Cardiology, Barts Heart CentreSaint Bartholomew's Hospital London UK

6. Department of CardiologyJ.W. Goethe University Frankfurt Germany

7. Division of CardiologySaiseikai Kumamoto Hospital Cardiovascular Center Kumamoto Japan

8. Boehringer Ingelheim PharmaIngelheim am Rhein Germany

9. Department of CardiologyRadboud University Medical Center Nijmegen the Netherlands

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/clc.23120

Reference23 articles.

1. Ten-year trends in the use of catheter ablation for treatment of atrial fibrillation vs. the use of coronary intervention for the treatment of ischaemic heart disease in Australia

2. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation

3. Periprocedural Stroke and Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation With Different Anticoagulation Management

4. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

5. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A retrospective analysis of anticoagulant safety among heart transplant recipients undergoing endomyocardial biopsy;Clinical Transplantation;2024-02

2. Evaluation of an adaptive, rule-based dosing algorithm to maintain therapeutic anticoagulation during atrial fibrillation ablation;Cardiovascular Digital Health Journal;2023-12

3. Meta-analysis of controlled studies on minimally interrupted vs. continuous use of non-vitamin K antagonist oral anticoagulants in catheter ablation for atrial fibrillation;EP Europace;2021-08-01

4. Changes in plasma concentrations of edoxaban and coagulation biomarkers according to thromboembolic risk and atrial fibrillation type in patients undergoing catheter ablation: Subanalysis of KYU‐RABLE;Journal of Arrhythmia;2020-12-29

5. Uninterrupted use of direct oral anticoagulants versus vitamin K antagonists for catheter ablation of atrial fibrillation with PVAC gold: incidence of silent cerebral microembolic events;Journal of Interventional Cardiac Electrophysiology;2020-09-19